Company: SISI
Filing Date: 2025-05-13
Form Type: 8-K
Source: 0001641172-25-009945
Chunk: 0

Company: SHINECO, INC.
Filing Date: 2025-05-13
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item
2.01 Completion of Acquisition or Disposition of Assets

On
May 12, 2025 (the “ Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“ Shineco Life Science”),
a subsidiary of Shineco, Inc. (the “ Company”), closed the acquisition of 75% of the equity interests in FuWang (HK) International
Company Limited, a company limited by shares incorporated in Hong Kong (“ FuWang (HK)”), pursuant to the stock purchase agreement
(the “ SPA”) dated March 20, 2025 with Yi Yang, the only shareholder of FuWang (HK) (the “ Seller”). On or prior
to the Closing Date, the closing conditions as set forth in the SPA were satisfied or otherwise waived by the parties thereto, and the
Seller has transferred 75% of the equity interests in FuWang (HK) to Shineco Life Science; therefore, FuWang (HK) became a direct subsidiary
of Shineco Life Science. In exchange, Shineco Life Science paid to the Seller RMB 63.89 million (approximately US$8.9 million)
in cash, and the Company issued 3,400,000 shares of the Company’s common stock, par value $0.001 per share (the “ Shares”)
and transferred the 71.42% equity interests in Dream Partner Limited it holds (the “ Dream Partner Shares”) to the Seller.

The
Shares were issued in reliance on Rule 902 of Regulation S promulgated under the Securities Act of 1933, as amended, and the Seller represented
that he was not a resident of the United States or a “ U. S. person” as defined in Rule 902(k) of Regulation S and was not
acquiring the Shares for the account or benefit of any U. S. person.

A
copy of the SPA is filed as Exhibit 2.1 hereto and is incorporated herein by reference. The above description of the SPA is qualified
in its entirety by reference to such exhibit.

Item
3.02 Unregistered Sales of Equity Securities